The CDMO Capacity Crunch With Discovery Labs' Audrey Greenberg and Iovance Biotherapeutics' Sumit Verma
Business Of Biotech
00:00
Do You Have a CDMO Partner?
I think it's very important to partner with the regulatory bodies up front, you know, in the early process. And I think it's important to also explore the potential designations like our met often drug or breakthrough designation to to start help facilitating access and discussions with regulatory bodies. So if we find a nice way to have those upfront conversations with that with with the regulatory body first and then have that same seamless communication and transparency with the CDMOs and working collaboratively to make sure we achieve those goals is going to be key to our future success.
Transcript
Play full episode
